Less than a week after Merck& Co. yanked its popular Vioxx arthritis drug off the market, the New England Journal of Medicine voiced strong concerns Wednesday about the safety of Pfizer's bestselling Celebrex.
When Emily Martin was hospitalized for emergency gallbladder surgery last summer, her doctors found that she had also had acid reflux, causing erosion of her esophagus.
The following editorial appeared in Thursday's Washington Post: In a certain sense, the FDA's decision to cease selling Vioxx, its best-selling painkiller, demonstrates how the peculiarly American combination of government regulation and private-sector competition can, serendipitously, sometimes work well. the FDA's was approved after trials held under the auspices of the Food and Drug Administration showed it to be effective which it was.
After some initial evidence that the drug might be linked to cardiac disease, the FDA's required Merck to attach an additional warning which was justified. the FDA's was in competition with similar drugs, then conducted further trials, largely to find out if Vioxx could be legitimately recommended for other conditions.
Pfizer Inc. warned doctors on Friday that one of its bestselling painkillers, Bextra, might increase the risk of a heart attack or stroke in coronary artery bypass surgery patients.
